| Autor: |
Qian He, Qunying Mao, Jialu Zhang, Fan Gao, Yu Bai, Bopei Cui, Jianyang Liu, Chaoqiang An, Qian Wang, Xujia Yan, Jinghuan Yang, Lifang Song, Ziyang Song, Dong Liu, Yadi Yuan, Jing Sun, Jincun Zhao, Lianlian Bian, Xing Wu, Weijin Huang, Changgui Li, Junzhi Wang, Zhenglun Liang, Miao Xu |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology, Vol 13 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1664-3224 |
| DOI: |
10.3389/fimmu.2022.949248 |
| Popis: |
To cope with the decline in COVID-19 vaccine-induced immunity caused by emerging SARS-CoV-2 variants, a heterologous immunization regimen using chimpanzee adenovirus vectored vaccine expressing SARS-CoV-2 spike (ChAd-S) and an inactivated vaccine (IV) was tested in mice and non-human primates (NHPs). Heterologous regimen successfully enhanced or at least maintained antibody and T cell responses and effectively protected against SARS-CoV-2 variants in mice and NHPs. An additional heterologous booster in mice further improved and prolonged the spike-specific antibody response and conferred effective neutralizing activity against the Omicron variant. Interestingly, priming with ChAd-S and boosting with IV reduced the lung injury risk caused by T cell over activation in NHPs compared to homologous ChAd-S regimen, meanwhile maintained the flexibility of antibody regulation system to react to virus invasion by upregulating or preserving antibody levels. This study demonstrated the satisfactory compatibility of ChAd-S and IV in prime-boost vaccination in animal models. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
